about
Oncogenes: The Passport for Viral Oncolysis Through PKR InhibitionKRAS Mutant Pancreatic Cancer: No Lone Path to an Effective TreatmentBiomarkers and Targeted Therapy in Pancreatic CancerClinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model.Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening.Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas.PP6 Disruption Synergizes with Oncogenic Ras to Promote JNK-Dependent Tumor Growth and Invasion.ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma.Calmodulin and PI3K Signaling in KRAS Cancers.Drugging RAS: Know the enemy.A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma.Structure-Guided Strategy for the Development of Potent Bivalent ERK Inhibitors.Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells.Aminoacylase 3 Is a New Potential Marker and Therapeutic Target in Hepatocellular Carcinoma.KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers.Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics.Lipoxin A4 Suppresses Estrogen-Induced Epithelial-Mesenchymal Transition via ALXR-Dependent Manner in Endometriosis.In Vivo Phosphoproteome Analysis Reveals Kinome Reprogramming in Hepatocellular Carcinoma.Isoform-selective activity-based profiling of ERK signaling
P2860
Q26739777-3C751EA6-9E41-41A9-9E09-C0C78CFF93CAQ26751520-6A654092-2C53-4E2E-B342-42D65A5AB87BQ26752755-11678400-AADE-48B4-AECB-8A7CE697D4F2Q33767369-62A64E9B-56C0-415E-98B1-3267CE1A7A95Q36192485-F3255F3D-75B7-4F24-99AE-D60335A78EFCQ38649987-DA2C0C4B-0612-4C49-ACC8-1FA9B9784C8AQ38704331-33D927A3-8DEA-4775-96F0-76C45C6EC990Q38758057-7339A087-6ADD-4416-BCA6-0E9960FE3733Q38809850-5907F9E8-B178-4E97-A9FB-7F6F4C4B88D7Q39182842-78647BC6-CCCE-4BFB-8C27-558AE9395B0DQ42017784-DE58AA4D-5BE9-4C1D-85CE-EEF6D63750AFQ46178714-0AF175EF-291F-4811-9F7B-B945044AB5A7Q47097618-4AD52E4A-CCF4-4409-8594-94257A97246AQ47148678-74882FE8-ADA3-4CB7-8A16-5D854805408AQ47563012-EBB20956-73CD-4367-AF43-45A0508C1997Q48611990-D3700BD9-3578-462D-83FD-218F3C7D43FDQ49167162-074948FE-4431-44BE-A6A2-6525BACAFF45Q50539197-BA42ABC8-B8C1-4164-9A14-8DD3C1F8344FQ54124926-1BC2D6A7-0099-4575-884D-E6003F76D4CBQ54964710-D93F0BAE-2CC7-4581-BC84-EAE6B2F1F093
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Targeting RAS-mutant cancers: is ERK the key?
@en
type
label
Targeting RAS-mutant cancers: is ERK the key?
@en
prefLabel
Targeting RAS-mutant cancers: is ERK the key?
@en
P2093
P2860
P1433
P1476
Targeting RAS-mutant cancers: is ERK the key?
@en
P2093
Adrienne D Cox
Andrea Wang-Gillam
Channing J Der
Meagan B Ryan
P2860
P304
P356
10.1016/J.TRECAN.2015.10.001
P577
2015-11-01T00:00:00Z